Angle PLC Total Voting Rights and Covington Subscription (6862W)
16 November 2017 - 7:23PM
UK Regulatory
TIDMAGL
RNS Number : 6862W
Angle PLC
16 November 2017
For immediate release 16 November 2017
ANGLE plc ("the Company")
Total Voting Rights and Covington Subscription
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, announces that, further to the announcement of 5 October
2017, 4,579,169 new ordinary shares of 10 pence each in the Company
("Ordinary Shares") were admitted to trading on AIM at 8.00 a.m.
today ("Covington Admission"). These Ordinary Shares were issued
pursuant to the Covington Subscription and Lock-in Deed ("Covington
Subscription Shares"). Pursuant to the Covington Subscription and
Lock-in Deed, Covington has agreed to not dispose of any interest
in the Covington Subscription Shares for a period of 18 months from
the date of Covington Admission, save for: prior written consent
being received from finnCap and WG Partners; or to a connected
person of Covington Fund II Inc.; or in acceptance of any takeover
offer; or where required by law or pursuant to an intervening court
order.
Following Covington Admission the total number of Ordinary
Shares in issue is 117,086,522. The figure of 117,086,522 should be
used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the FCA's Disclosure Guidance and Transparency Rules.
Capitalised terms not otherwise defined in this announcement
shall have the same meaning ascribed to such terms in the
announcement entitled "Acquisition and Fundraising" released on 5
October 2017 unless the context requires otherwise.
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint
Broker)
Corporate Finance - Adrian
Hargrave, Simon Hicks, Kate
Bannatyne
Corporate Broking - Alice Lane,
Nikita Jain +44 (0) 207 220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks,
Andrew Craig, Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Mo Noonan, Stephanie
Cuthbert +44 (0) 203 727 1000
Kimberly Ha (US) +1 212 850 5612
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world-leading liquid biopsy company commercialising a
disruptive platform technology that can capture cells circulating
in blood, such as cancer cells, even when they are as rare in
number as one cell in one billion blood cells, and harvest the
cells for analysis.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, India, China,
Japan and Australia and three extensive families of patents are
being progressed worldwide. The system is based on a microfluidic
device that captures live cells based on a combination of their
size and compressibility. Parsortix has a CE Mark for Europe and
FDA authorisation is in process for the United States.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
The analysis of the cells that can be harvested from patient
blood with ANGLE's Parsortix(TM) system has the potential to help
deliver personalised cancer care offering profound improvements in
clinical and health economic outcomes in the treatment and
diagnosis of various forms of cancer.
The global increase in cancer to a 1 in 3 lifetime incidence is
set to drive a multi-billion dollar clinical market. The
Parsortix(TM) system is designed to be compatible with existing
major medtech analytical platforms and to act as a companion
diagnostic for major pharma in helping to identify patients that
will benefit from a particular drug and then monitoring the drug's
effectiveness.
As well as cancer, the Parsortix(TM) technology has the
potential for deployment with several other important cell types in
the future.
ANGLE stock trades on the AIM market of the London Stock
Exchange under the ticker symbol AGL and in New York on the OTC-QX
under the ticker symbol ANPCY. For further information please
visit: www.angleplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVRVQLBFDFFFFBK
(END) Dow Jones Newswires
November 16, 2017 03:23 ET (08:23 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2024 to May 2024
Angle (LSE:AGL)
Historical Stock Chart
From May 2023 to May 2024